Malaria Vaccine Trial – Completion of Vaccinations
The Clinical Trial Team, led by Professor Kwadwo Koram, now the Director of the Institute, has completed the last set of vaccinations for the first ever Phase I Malaria Vaccine Trial at the Institute.
The two-year trial of the recombinant malaria vaccine, EBA-175,is being conducted in the purpose-built Prince Alwaleed bin Talal Clinical Trials facility. The randomized, controlled, double-blinded, dosage-escalation clinical trial of the EBA-175 vaccine is the first ever to evaluate the safety and immunogenicity of this protein based malaria vaccine candidate in a population residing in a malaria endemic area. One hundred and eleven people between the ages of eighteen and forty gave consent and were screened for the study, of whom 60 qualified and were enrolled.
Beginning with twenty subjects in a low (5µg) dose cohort, followed by a second cohort of twenty administered with a medium dose (20μg), the final cohort, received a high dose (80μg) of the vaccine. All three groups received three doses of the vaccine in a 0-1-6 schedule, in which they received an initial dose, one a month later and a final dose six months from the initial. The final group completed their vaccinations and early post vaccination observations in October 2011 with no immediate reactions. Researchers at the institute will continue to monitor the volunteers over the next 6 months for long term safety.
The trial was sponsored by the Division of Microbiology (DMID), National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).